These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 23908187)

  • 1. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
    Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
    Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
    Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
    Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
    Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
    Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
    Clin Exp Rheumatol; 2016; 34(6):1065-1071. PubMed ID: 27607411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
    Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
    Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
    Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
    J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
    Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
    Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.
    Sandström T; Rantalaiho V; Yli-Kerttula T; Kautiainen H; Malmi T; Karjalainen A; Uusitalo T; Julkunen H; Kaipiainen-Seppänen O; Paimela L; Puolakka K; Uutela T; Möttönen T; Hannonen P; Leirisalo-Repo M; Laasonen L; Kauppi M;
    J Rheumatol; 2020 Aug; 47(8):1160-1164. PubMed ID: 31732558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
    Rantalaiho V; Korpela M; Laasonen L; Kautiainen H; Järvenpää S; Hannonen P; Leirisalo-Repo M; Blåfield H; Puolakka K; Karjalainen A; Möttönen T;
    Arthritis Res Ther; 2010; 12(3):R122. PubMed ID: 20576092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
    Karstila KL; Rantalaiho VM; Mustonen JT; Möttönen TT; Hannonen PJ; Leirisalo-Repo M; Kaipiainen-Seppänen OA; Karjalainen AH; Korpela MM;
    Clin Exp Rheumatol; 2010; 28(1):73-8. PubMed ID: 20346242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.
    Markusse IM; Akdemir G; Dirven L; Goekoop-Ruiterman YP; van Groenendael JH; Han KH; Molenaar TH; Le Cessie S; Lems WF; van der Lubbe PA; Kerstens PJ; Peeters AJ; Ronday HK; de Sonnaville PB; Speyer I; Stijnen T; Ten Wolde S; Huizinga TW; Allaart CF
    Ann Intern Med; 2016 Apr; 164(8):523-31. PubMed ID: 27089068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
    Kuusalo LA; Puolakka KT; Kautiainen H; Alasaarela EM; Hannonen PJ; Julkunen HA; Kaipiainen-Seppänen OA; Korpela MM; Möttönen TT; Paimela LH; Peltomaa RL; Yli-Kerttula TK; Leirisalo-Repo M; Rantalaiho VM;
    Clin Exp Rheumatol; 2016; 34(6):1038-1044. PubMed ID: 27494516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
    Klarenbeek NB; Güler-Yüksel M; van der Kooij SM; Han KH; Ronday HK; Kerstens PJ; Seys PE; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Jun; 70(6):1039-46. PubMed ID: 21415052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.